Global & USA Cancer Biomaker Market to 2018 (Identification, Technologies, Market Analysis, Competitor Profiles, Companion Diagnostic Co-Development, Business Strategies, Industry Trends, and Pipeline Analysis) - Market Size, Trends, and Forecasts Available Online by Researchmoz.us

ALBANY, New York, July 21, 2014 /PRNewswire/ --

ResearchMoz presents this most up-to-date research on Global & USA Cancer Biomaker Market to 2018  - Market Size, Trends, and Forecasts

ResearchMoz presents this most up-to-date research on Global & USA Cancer Biomaker Market  to 2018 (Identification, Technologies, Market Analysis, Competitor Profiles, Companion Diagnostic Co-Development, Business Strategies, Industry Trends, and Pipeline Analysis.

GLOBAL & USA CANCER BIOMARKER MARKET to 2018 (Identification, Technologies, Market Analysis, Competitor Profiles, Companion Diagnostic Co-development, Business Strategies, Industry Trends, and Pipeline Analysis)" by Kelly Scientific Publications is a comprehensive report on the cancer biomarker industry and its impact on the health system. This report tackles the growing market interest in oncogenic biomarkers, personalized medicine, companion diagnostics and the associated market environment. 

To view the table of contents for this market research report please visit: http://www.researchmoz.us/global-and-usa-cancer-biomaker-market-to-2018-identification-technologies-market-analysis-competitor-profiles-companion-diagnostic-co-development-business-strategies-industry-trends-and-pipeline-analysis-report.html

Cancer biomarkers are molecular or genetic moieties (e.g., cells, proteins/peptides, genetic mutations, gene products, enzymes, or hormones) that not only are readily identifiable, but easily quantified in the lab setting. They function primarily to identify or correlate significantly with the severity or occurrence of a certain disease state. The rise in number of oncogenic biomarkers over the last number of years has massive potential in the healthcare industry and serves to propel both the personalized medicine and companion diagnostic markets. 

One of the most import aspects of biomarkers is their use to diagnose and assess the progress of disease states in patients. As quantitative markers, these agents also offer the ability to monitor response to certain drug treatments and so are important in the area of personalized medicine. 

Executive Summary: 

This is a comprehensive account of the market size, segmentation, key players, SWOT analysis, influential technologies, and business and economic environments. The report is supported by 280 tables & figures over 232 pages. The personalized medicine (global) market is presented as follows:

• By Company (e.g., 23andMe, AFFYMETRIX, ATOSSA GENETICS, NODALITY, deCode /Amgen, CELERA, MYRIAD, FOUNDATION MEDICINE, GENOMIC HEALTH)
• By Geography (Global, US)
• By Sub-market (Global Biomarker Market, Cancer Biomarker Market, Global Cancer Profiling Technology Market )

A wealth of financial data & business strategy information is provided including: 

• Up-to-date company financials, sales & revenue figures
• Revenue and market forecasts up to 2018
• Business model strategies for diagnostic, pharmaceutical and biotechnology companies
• Therapeutics and Companion Diagnostics (e.g., BRAC Analysis, Oncotype Dx , KRAS Mutations)
• Comprehensive account of company product financials, portfolios & kits

SWOT, Economic & Regulatory Environment specifics include: 

• Key strengths, weaknesses and threats influencing leading player position within the market
• Technologies driving the market (e.g., New-Generation Sequencing Technologies, Ultra-High Throughput Sequencing)
• Top fastest growing market segments and emerging opportunities
• Top pharmaceutical companies within the cancer biomarker market 
• Comprehensive product portfolios, R&D activity and pipeline therapeutics 
• M&A activity and future strategies of top companies
• Approved biomarker companion diagnostic tests
• High demand and Unmet Need Enhances the Global Biomarker Market   
• FDA Support Increases Biomarker Development  
• More Streamlined Clinical Trials
• Significant Growth of High-Impact Oncogenic Biomarker Research 
• Advancements in Discovery Technologies
• Challenges of the Oncogenic Biomarker Market
• Variability of Biomarkers within Different Cancer Subtypes
• Integration of Genomics and Biomarker Diagnostics into the Healthcare System
• Ethical Considerations

Individualized, targeted or personalized medicine aims to increase the efficacy of therapeutics via genetic testing and companion diagnostics. Personalized therapeutics and associated companion diagnostics will be more specific and effective thereby giving pharma/biotech companies a significant advantage to recuperate R&D costs. Personalized medicine will reduce the frequency of adverse drug reactions and therefore have a dramatic impact on health economics. Developmental and diagnostic companies will benefit from lower discovery and commercialization costs and more specific market subtypes. 

This report describes the current technologies that are propelling the cancer biomarker and companion diagnostic market. It examines the current genetic diagnostic tests and companion diagnostic assays that are in use by the medical and pharmaceutical industry today. Current developments in personalized medicine and the pharmacogenomics revolution are discussed. The emerging trends that appear in the global market and the most developed market (US) are elucidated and analysed. This study reveals market figures of the overall biomarker market and the cancer biomarker space (2013-2018). Forecast projections and future growth rates are provided to give the reader a forthcoming perspective of this growing industry.

The study also provides a comprehensive financial, business strategy and product review of key players in the cancer biomarker industry. Strategic drivers and restraints of this market are revealed and market opportunities and challenges are identified. 

In summary, the cancer biomarker and associated companion diagnostic market have huge opportunities for growth. This industry will revolutionize the healthcare system and will improve therapeutic effectiveness and reduce the severity of adverse effects. It has enormous potential for investment and the emergence of genetic-based in vitro diagnostics. 

Related & Recently Added Reports by Researchmoz.us to its store 

Sienna Cancer Diagnostics Ltd - Product Pipeline Analysis, 2014 Update : Metal smelting is a process of extracting metal from its ore which is mixed with heat generating or purifying substances such as coke or limestone. Smelted or pure gold finds its application in various fields such as medical, dental, electronics and industrial application. While purchasing gold ore, investors are buying the insignificant material that sticks to pure gold. If buying gold as an asset, it is a better to purchase smelted gold. Along with melting gold into bar, smelter removes the impurities from gold using heat, pressure and certain chemicals. Hence, private and institutional investors who invest in gold coins, scrap gold and gold dust prefer gold smelting. See More details : http://www.researchmoz.us/sienna-cancer-diagnostics-ltd-product-pipeline-analysis-2014-update-report.html

Breast Cancer Therapeutics in Major Developed Markets to 2020 : The Major Developed Markets to 2020 - Approval of Novel Therapies to Support Continued Dominance of HER2 Targeted Drugs ', which provides in-depth analysis of breast cancer therapeutics market within the eight major geographies of the US, Canada, the top five geographies in Europe (the UK, France, Germany, Spain and Italy) and Japan. The report provides an estimation of market size for 2013, along with market forecast until 2020. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis. The breast cancer therapeutics market in the eight major markets. See more Details: http://www.researchmoz.us/breast-cancer-therapeutics-in-major-developed-markets-to-2020-approval-of-novel-therapies-to-support-continued-dominance-of-her2-targeted-drugs-report.html

Prostate Cancer Treatment Drugs Markets in China: China's demand for Prostate Cancer Treatment Drugs has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow. This new study examines China's economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2003, 2008 and 2013) and long-term forecasts through 2018 and 2023 are presented. Major producers in China are profiled. See More details : http://www.researchmoz.us/prostate-cancer-treatment-drugs-markets-in-china-report.html

Explorer More Therapeutic Area @ http://www.researchmoz.us/therapeutic-area-market-reports-37.html

About Us

ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.

For More Information Kindly Contact:

90 Sate Street, Suite 700

Albany, NY 12207

Website@ http://www.researchmoz.us/

Email: sales@researchmoz.us    
Tel: +1-518-618-1030

USA - Canada Toll Free: 866-997-4948